Mature Pseudomonas aeruginosa Biofilms Prevail Compared to Young Biofilms in the Presence of Ceftazidime
52
Citation
16
Reference
10
Related Paper
Citation Trend
Abstract:
ABSTRACT Phenotypic tolerances to antibiotics of mature and young Pseudomonas aeruginosa PAO1 biofilms and released planktonic bacteria were compared for four antibiotics. Resistance levels were similar for gentamicin and ciprofloxacin but differed for ceftazidime and meropenem. β-Lactamase mapping showed that, after 5 h of ceftazidime exposure, mature biofilms produced more β-lactamase than young biofilms, facilitating the growth of released planktonic bacteria. This shows the importance of early treatment and choice of antibiotics for P. aeruginosa biofilm infections.Keywords:
Pseudomonadales
Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients The Meropenem Study Group of Leuven, London and Nijmegen The Meropenem Study Group of Leuven, London and Nijmegen Search for other works by this author on: Oxford Academic PubMed Google Scholar *The members of the Study Group are as follows: M. A. Boogaerts, H. Demuynck, N. Mestdagh and L. Verbist, University Hospital Gasthuisberg, Leuven, Belgium; A. H. Goldstone, H. C. Kelsey and S. Machin, University College Hospital, London, UK; B. E. De Pauw, J. P. Donnelly and J. M. M. Raemaekers, University Hospital St Radboud, Nijmegen, The Netherlands; and G. Atkinson and K. J. Williams, Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK Author Notes Journal of Antimicrobial Chemotherapy, Volume 36, Issue 1, July 1995, Pages 185–200, https://doi.org/10.1093/jac/36.1.185 Published: 01 July 1995 Article history Received: 19 April 1994 Revision received: 08 September 1994 Accepted: 24 February 1995 Published: 01 July 1995
Empirical treatment
Carbapenem
Cite
Citations (74)
Hematology
Empirical treatment
Cite
Citations (39)
Suspensions obtained from five Pseudomonas aeruginosa pyocinogenic strains showed inhibitory and variable activity against bacterial strains belonging to the Nocardiaceae, Micrococcaceae, Neisseriaceae, Streptococcaceae, Vibrionaceae, Enterobacteriaceae, and Pseudomonadaceae families. Under special conditions, the same pyocinogenic P. aeruginosa strain can be affected by it own suspensions. These pyocinlike particles could be considered as a regulatory factor acting on the rate and size of the population growth.
Pseudomonadales
Neisseriaceae
Cite
Citations (1)
Ceftazidime is commonly used as monotherapy of cancer patients with fever and neutropenia. Concern, however, has been raised regarding potential for drug resistance due to its widespread use. Meropenem is a new carbapenem with more extended antibacterial spectrum including anaerobes. It provides better coverage against gram positives. Hence, it may offer an advantage over ceftazidime.We prospectively treated 49 patients hospitalized for fever (> 38 degrees C) and neutropenia (ANC < or = 500/cmm) with meropenem. We compared their outcome with 50 patients who consecutively received ceftazidime in the immediate past for the same indication.Comparison of demographic features between the 2 groups revealed no differences in age, gender, type of neoplasm, number of patients with prior antibiotic use, number of days since chemotherapy, absolute neutrophil count and number of patients previously or already hospitalized. Duration of fever, duration of neutropenia and number of patients with pyrexia of undetermined origin were also similar. Therapeutic outcome was same between the two groups. Eighty four percent of patients receiving meropenem and 79% receiving ceftazidime required no modification of the initially assigned therapeutic regimen. Two patients receiving meropenem died. Toxicity was minimal.We conclude that meropenem offers no significant advantage over ceftazidime in the management of neutropenic febrile patients.
Cite
Citations (11)
Cite
Citations (2)
Pseu.do.mon.a.da' ce.ae. M.L. fem. n. Pseudomonas type genus of the family; -aceae ending to denote family; M.L. fem. pl. n. Pseudomonadaceae the Pseudomonas family. Proteobacteria / Gammaproteobacteria / Pseudomonadales / Pseudomonadaceae
Pseudomonadales
Cite
Citations (6)
In vivo construction of a hybrid pathway for metabolism of 4-nitrotoluene in Pseudomonas fluorescens
Pseudomonas fluorescens 410PR grows on 4-nitrobenzoate but does not metabolize 4-nitrotoluene. The TOL pWW0 delta pm plasmid converts 4-nitrotoluene into 4-nitrobenzoate through its upper pathway, but it does not metabolize 4-nitrobenzoate. P. fluorescens 410PR(pWW0 delta pm) transconjugants were isolated and found to be able to grow on 4-nitrotoluene. This phenotype was stable after growth for at least 300 generations without any selective pressure. P. fluorescens 410PR(pWW0 delta pm) converted 4-nitrotoluene into 4-nitrobenzoate via 4-nitrobenzylalcohol and 4-nitrobenzaldehyde. 4-Nitrobenzoate was metabolized via 4-hydroxylaminobenzoate and finally yielded NH4+ and 3,4-dihydroxybenzoate, which was mineralized.
Pseudomonas fluorescens
Pseudomonadales
Cite
Citations (27)
In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7% of the patients treated with meropenem and in 95.3% of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2% in the meropenem group and 4.6% in the ceftazidime group.Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.
Empiric therapy
Cite
Citations (16)
The effect of a commonly used biocide, 1,2-benzisothiazolin-3-one (BIT) on ppGpp accumulation in the pathogen, Pseudomonas aeruginosa PAO1, and an environmental isolate, Ps. fluorescens, was examined. It is concluded that BIT is able to induce a stringent response in Ps. aeruginosa and Ps. fluorescens, determined by the rapid accumulation of ppGpp following addition of BIT to exponentially-growing cells. Western blot analysis of whole-cell extracts with anti-RelA antibody demonstrated that both species contain a RelA homologue. This is the first report of a RelA-like protein in pseudomonads.
Pseudomonas fluorescens
Pseudomonadales
Biocide
Cite
Citations (13)
This trial assessed the efficacy and safety of meropenem versus ceftazidime as empirical monotherapy for febrile neutropenia in paediatric cancer patients. In a prospective randomized study, 172 evaluable febrile episodes in the meropenem arm and 170 episodes in the ceftazidime arm were analysed for the clinical and microbiological response dependent on the kind of infection. About half the episodes were classified as fever of unknown origin (FUO) and the remainder as microbiologically or clinically documented infections. The most frequently documented infections in both arms were bacteraemias (22.1 versus 26.5%), predominantly caused by Gram-positive organisms (57.9 versus 71.1%). The success rate of the initial monotherapy differed significantly between the two arms and was 55.8% in the meropenem and 40.0% in the ceftazidime arm (P = 0.003). In addition, a significantly longer duration of fever and of antimicrobial therapy was observed in the ceftazidime arm than in the meropenem arm (median 5 versus 4 days, P = 0.022, and 7 versus 6 days, P = 0.009, respectively). With respect to the kind of infection, differences between the two arms were significant only in episodes classified as FUO but not in documented infections. In both arms, side effects were minimal. Despite the greater response rate for meropenem in FUO, the fact that ceftazidime has been proven to be as effective as meropenem in documented infections in the present study suggests that both drugs are useful as empirical monotherapy in febrile paediatric cancer patients.
Cite
Citations (64)